TG Therapeutics | TGTX - Operating Expenses


TG Therapeutics reported $106.3M in Operating Expenses for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 702.61M
Cash and Equivalent USD 278.86M
Cost of Sales USD 18.94M
Current Assets USD 663.96M
Current Liabilities USD 171.89M
Debt USD 8.98M
EBIT USD 34.84M
EBITDA USD 12.28M
Employees 338
EPS Earnings Per Share USD 0.17
Equity Capital and Reserves USD 276.43M
Gross Profit on Sales USD 122.21M
Interest Expense on Debt USD 6.72M
Loan Capital USD 245.04M
Market Capitalization USD 4.97B
Net Income USD 28.19M
Operating Expenses USD 106.31M
Operating Profit USD 34.84M
Ordinary Share Capital USD 158.03M
PE Price to Earnings USD 88.77
Pre-Tax Profit USD 30.92M
Sales Revenues USD 141.1M
Selling and Administration Expenses USD 12.04M
Stock USD 155.2M
Trade Creditors USD 134.02M
Trade Debtors USD 231.52M

Operating Expenses Change Date
AbbVie USD 9.71B 96M Jun/2025
Alaunos Therapeutics USD 759K 391K Dec/2024
Amgen USD 6.52B 337M Jun/2025
Ardelyx USD 112.06M 4.06M Jun/2025
Arrowhead Research USD 193.32M 31.81M Jun/2025
Bayer EUR 10.73B 688M Jun/2025
Biogen USD 1.79B 326.1M Jun/2025
Corcept Therapeutics USD 167.76M 13.96M Jun/2025
Dynavax Technologies USD 81.01M 10.78M Jun/2025
Gilead Sciences USD 4.35B 80M Jun/2025
J&J USD 16.8B 8.54B Jun/2025
Novartis USD 9.97B 1.02B Jun/2025
PTC Therapeutics USD 213.73M 7.86M Jun/2025
Regeneron Pharmaceuticals USD 2.6B 159.1M Jun/2025
Roche Holding CHF 11.43B 1.48B Dec/2024
TG Therapeutics USD 106.3M 5.93M Jun/2025
Vertex Pharmaceuticals USD 1.81B 71.4M Jun/2025